## 1 Supplementary Table S4 Virus sensitivity to NA inhibitor compounds in vitro.

| Compound                             | IC <sub>50</sub> value <sup>a</sup> |               |                |                                |
|--------------------------------------|-------------------------------------|---------------|----------------|--------------------------------|
|                                      | MDk/W452(H5N8)                      | En/W149(H5N1) | MDk/W401(H5N1) | CA/04(H1N1) <sub>H274Y</sub> c |
| Oseltamivir carboxylate <sup>b</sup> | 2.01                                | 0.65          | 1.88           | 86.54                          |
| Peramivir                            | 0.28                                | 0.37          | 0.85           | 9.56                           |
| Zanamivir                            | 0.61                                | 0.49          | 1.26           | 0.62                           |

<sup>&</sup>lt;sup>a</sup>IC<sub>50</sub> value: mean nM of triplicate reactions.

3

4

5

- <sup>c</sup>The 2009 pandemic virus CA/04(H1N1), A/California/04/2009(H1N1), was modified to contain the H274Y resistance
- marker in its NA gene, which served as a positive control against the NA inhibitor compounds tested.

<sup>&</sup>lt;sup>b</sup>Oseltamivir carboxylate is the active form of oseltamivir.